Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, 980 Great West Road, Brentford, Middlesex, TW8 9GS
Naramig 2.5 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Tablets. |
Tablets containing 2.5 mg of naratriptan as naratriptan hydrochloride.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Naratriptan |
Naratriptan has been shown to be a selective agonist for 5 hydroxytryptamine1 (5-HT1) receptors mediating vascular contraction. This receptor is found predominantly in intracranial (cerebral and dural) blood vessels. Naratriptan is indicated for the acute treatment of migraine attacks with or without aura. |
| List of Excipients |
|---|
|
Tablet core: Microcrystalline cellulose Film-coat: Methylhydroxypropylcellulose |
2, 4, 6 or 12 tablets in a double foil blister pack or child-resistant foil blister pack.
Not all pack sizes may be marketed.
Glaxo Wellcome UK Ltd, trading as GlaxoSmithKline UK, 980 Great West Road, Brentford, Middlesex, TW8 9GS
PL 10949/0273
28 April 2002
| Drug | Countries | |
|---|---|---|
| NARAMIG | Australia, Brazil, Germany, Estonia, Spain, Finland, France, Israel, Lithuania, Netherlands, Poland, Singapore, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
